Which antiplatelet agent is known for having a faster offset of action post discontinuation?

Which antiplatelet agent is known for having a faster offset of action post discontinuation?

• A. Clopidogrel
• B. Ticagrelor
• C. Prasugrel
• D. Aspirin

Answer: (B)

Ticagrelor is recognized for having a faster offset of action following discontinuation compared to other antiplatelet agents. This is primarily due to its pharmacodynamics and the fact that it is a reversible inhibitor of the P2Y12 receptor. After stopping ticagrelor, platelet function can restore more quickly because the drug does not bind permanently to the receptor, allowing the body to regain normal platelet function in a relatively short time frame. In contrast, clopidogrel and prasugrel, which are prodrugs, require metabolic activation and have a longer duration of action due to their irreversible binding to the P2Y12 receptor. Aspirin, while not a direct comparison, also has a longer-lasting effect on platelet aggregation because it irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, affecting their function for the lifespan of the platelet. Thus, patients who require a rapid restoration of platelet function after discontinuation of an antiplatelet agent would benefit from ticagrelor.

Ticagrelor is recognized for having a faster offset of action following discontinuation compared to other antiplatelet agents. This is primarily due to its pharmacodynamics and the fact that it is a reversible inhibitor of the P2Y12 receptor. After stopping ticagrelor, platelet function can restore more quickly because the drug does not bind permanently to the receptor, allowing the body to regain normal platelet function in a relatively short time frame.

In contrast, clopidogrel and prasugrel, which are prodrugs, require metabolic activation and have a longer duration of action due to their irreversible binding to the P2Y12 receptor. Aspirin, while not a direct comparison, also has a longer-lasting effect on platelet aggregation because it irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, affecting their function for the lifespan of the platelet. Thus, patients who require a rapid restoration of platelet function after discontinuation of an antiplatelet agent would benefit from ticagrelor.